These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 8609411)

  • 1. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
    Gajewski TF; Fallarino F; Uyttenhove C; Boon T
    J Immunol; 1996 Apr; 156(8):2909-17. PubMed ID: 8609411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
    Gajewski TF
    J Immunol; 1996 Jan; 156(2):465-72. PubMed ID: 8543795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules.
    Yang G; Hellström KE; Hellström I; Chen L
    J Immunol; 1995 Mar; 154(6):2794-800. PubMed ID: 7533183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
    Fallarino F; Ashikari A; Boon T; Gajewski TF
    Int Immunol; 1997 Sep; 9(9):1259-69. PubMed ID: 9310829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of B7-1-expressing host antigen-presenting cells for the eradication of B7-2 transfected P815 tumor cells.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1998 Dec; 161(12):6552-8. PubMed ID: 9862681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4.
    Horspool JH; Perrin PJ; Woodcock JB; Cox JH; King CL; June CH; Harlan DM; St Louis DC; Lee KP
    J Immunol; 1998 Mar; 160(6):2706-14. PubMed ID: 9510170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4.
    Mandelbrot DA; Oosterwegel MA; Shimizu K; Yamada A; Freeman GJ; Mitchell RN; Sayegh MH; Sharpe AH
    J Clin Invest; 2001 Apr; 107(7):881-7. PubMed ID: 11285307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
    Fallarino F; Uyttenhove C; Boon T; Gajewski TF
    J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma.
    Prell RA; Kerkvliet NI
    J Immunol; 1997 Mar; 158(6):2695-703. PubMed ID: 9058803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
    Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
    Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
    J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A; Cavallo F; Bellone M; Heltai S; Iezzi G; Tornaghi P; Nabavi N; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1996 Aug; 26(8):1851-9. PubMed ID: 8765031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.
    Judge TA; Wu Z; Zheng XG; Sharpe AH; Sayegh MH; Turka LA
    J Immunol; 1999 Feb; 162(4):1947-51. PubMed ID: 9973463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.
    Yeh KY; Pulaski BA; Woods ML; McAdam AJ; Gaspari AA; Frelinger JG; Lord EM
    Cell Immunol; 1995 Oct; 165(2):217-24. PubMed ID: 7553886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7.2 expressed by T cells does not induce CD28-mediated costimulatory activity but retains CTLA4 binding: implications for induction of antitumor immunity to T cell tumors.
    Greenfield EA; Howard E; Paradis T; Nguyen K; Benazzo F; McLean P; Höllsberg P; Davis G; Hafler DA; Sharpe AH; Freeman GJ; Kuchroo VK
    J Immunol; 1997 Mar; 158(5):2025-34. PubMed ID: 9036945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo.
    Sigal LJ; Reiser H; Rock KL
    J Immunol; 1998 Sep; 161(6):2740-5. PubMed ID: 9743331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
    Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
    J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.